Company intelligence / Profile preview

Zetagen Therapeutics

Syracuse, New York, United Stateszetagen.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Zetagen’s lead candidate, ZetaMet™ (Zeta‑BC‑003), is in a Phase IIa clinical trial for metastatic breast cancer in the spine. The company has received multiple FDA Breakthrough Designations and has published results from compassionate use cases. Preclinical data support efficacy of other pipeline assets targeting metastatic cancers to bone and soft tissue organs.

Therapeutic areas: OncologyOther
Modalities: Small moleculesProprietary drug-carrier platformsHydrogel carriers
Industry: Biotech

Drug pipeline

8 assets

ZetaMAST

Preclinical

7 more assets in the full pipeline.

Request access →

Partnerships

Foley & Lardner LLP – intellectual property counselUniversity of British Columbia – clinical trial site for Phase IIa study

Beyond the preview

Go deeper on Zetagen Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zetagen Therapeutics.

Explore the full profile